glp 1 for parkinson's The glucagon-like peptide (GLP) receptor as a therapeutic target in disease: mechanisms of action A new Science Perspective highlights

SUIT-2 and MIA PaCa-2 (Japanese Cancer Resource Bank, Tokyo, Japan)

Interleukin-6 and prostate cancer: current developments and unsolved questions

The mechanism by which Zepbound and other GLP-1 receptor agonists affect digestive function provides important context for understanding potential reflux symptoms

The new vials will be available exclusively to people who pay out of pocket through LillyDirect, a company platform that helps coordinate telehealth services and fill prescriptions for patients

10,33 With regard to the secondary outcome of HF hospitalisation, the results were neutral, with LEADER showing a non-significant relative risk reduction (RRR) of 13% with liraglutide compared with placebo and SUSTAIN-6 showing no significant difference between the semaglutide and placebo treatment groups